Held in Chicago, ACC 2025 is the premier event for exploring breakthroughs in cardiovascular research. Attendees will benefit from high-impact sessions, hands-on workshops, and networking opportunities. Our team will share key insights and discuss initiatives aimed at addressing challenges in heart health. Whether you’re looking to expand your research capabilities or collaborate on innovative treatments, we’re eager to connect with you.
Richmond Pharmacology highlights encouraging first-in-human results for Regeneron's investigational RNAi therapy in MASLD
November 12, 2026
NEJM publication and AASLD presentation reports that 79% of treated participants with MASLD and available measurements achieved normal liver fat levels at Week 24 after a single dose of CIDEBsiRNA, alongside improvements in markers of liver injury.
Richmond Pharmacology is excited to join the AHA Scientific Sessions 2026 in 14–16 November 2026, on 14–16 November 2026, hosted by the American Heart Association.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
